AC Immune (ACIU) Net Cash Flow Growth (1y) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 198.34% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 467.41% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14,223.53% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 453.08% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -125.22% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 53.46% |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -156.67% |
| Sep 30, 2025 | 111.81% |
| Jun 30, 2025 | 384.83% |
| Mar 31, 2025 | 30.66% |
| Dec 31, 2024 | -95.96% |
| Sep 30, 2024 | -137.98% |
| Jun 30, 2024 | 83.74% |
| Mar 31, 2024 | -195.18% |
| Dec 31, 2023 | 527.10% |
| Sep 30, 2023 | 51.73% |
| Jun 30, 2023 | -485.15% |
| Mar 31, 2023 | 204.96% |
| Dec 31, 2022 | -12.80% |
| Sep 30, 2022 | -67.53% |
| Jun 30, 2022 | 109.83% |
| Mar 31, 2022 | -131.07% |
| Dec 31, 2021 | 34.09% |
| Sep 30, 2021 | -1,408.62% |
| Jun 30, 2021 | -822.02% |
| Mar 31, 2021 | -8.54% |
| Dec 31, 2020 | 8.06% |
| Sep 30, 2020 | -111.77% |
| Jun 30, 2020 | 64.95% |
| Mar 31, 2020 | -116.09% |
| Dec 31, 2019 | 56.42% |
| Sep 30, 2019 | -93.41% |
| Jun 30, 2019 | -110.73% |
| Mar 31, 2019 | 531.43% |
| Dec 31, 2018 | -100.14% |
| Sep 30, 2018 | 100.32% |
| Jun 30, 2018 | 25.01% |
| Mar 31, 2018 | -22.81% |
| Dec 31, 2017 | 312,901.59% |
| Sep 30, 2017 | -40,096.46% |
| Jun 30, 2017 | -169.88% |
| Mar 31, 2017 | -49.51% |
| Dec 31, 2016 | -143.59% |